



NDA 22-145/S-018

**SUPPLEMENT APPROVAL**

Merck Sharp & Dohme Corp.  
Attention: Robert A. Fromtling, Ph.D.  
Director, Worldwide Regulatory Affairs  
126 E. Lincoln Ave.  
P.O. Box 2000, RY33-212  
Rahway, New Jersey 07065-0900

Dear Dr. Fromtling:

Please refer to your Supplemental New Drug Application (sNDA) dated February 16, 2011, received February 16, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ISENTRESS™ (raltegravir potassium) Tablets, 400mg.

We acknowledge receipt of your amendment dated March 25, 2011.

This “Changes Being Effected” supplemental new drug application provides for the addition of “hepatic failure (with and without associated hypersensitivity) in patients with underlying liver disease and/or concomitant medications” in subsection 6.2, Postmarketing Experience, of the package insert (PI) with a corresponding update to the patient package insert (PPI).

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your March 25, 2011, submission includes final printed labeling (FPL) for your package insert and patient package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Amalia Himaya, Regulatory Project Manager, at (301) 796-3391 or the Division’s main number at (301) 796-1500.

Sincerely,

*{See appended electronic signature page}*

Debra Birnkrant, M.D.  
Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

KENDALL A MARCUS  
04/11/2011